KDNY — Chinook Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.90bn
- $2.60bn
- $6.13m
Brief: Chinook Therapeutics Presents Bion-1301 Interim Phase 1/2 Data In Patients With Iga Nephropathy (Igan) At The 58Th Era-Edta Virtual Congress
Chinook Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Chinook Therapeutics Provides Business Update And Reports First Quarter 2021 Financial Results
Chinook Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Chinook Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Chinook Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Chinook Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Chinook Therapeutics Files For Mixed Shelf Of Up To $275 Mln
Brief: Chinook Therapeutics Reports Q4 Loss Per Share $1.24
Brief: Chinook Therapeutics Announces First Patient Dosed In Phase 2 Affinity Basket Study Of Atrasentan
Brief: Chinook Therapeutics Announces Update On Non-Renal Legacy Programs
Brief: Chinook Therapeutics Inc Files For Non Timely 10-K
Brief: Chinook Therapeutics Announces Upcoming Data Presentations At ISN World Congress Of Nephrology 2021 And 58Th ERA-EDTA Congress
Brief: Chinook Therapeutics Announces First Patient Enrolled In Pivotal Phase 3 Align Study Of Atrasentan
Brief: Chinook Therapeutics And Evotec Announce Collaboration To Discover And Develop Medicines For Chronic Kidney Diseases
Brief: Evotec Enters Strategic Partnership WIth Chinook For Chronic Kidney Disease
Brief: Chinook Receives Rare Pediatric Disease Designation From U.S. Food And Drug Administration For CHK-336 For Treatment Of Primary Hyperoxaluria
Brief: Chinook Enters License Agreement With Morehouse School Of Medicine
Brief: Chinook Therapeutics Names Eric Bjerkholt As Chief Financial Officer